---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-058893"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:48:54.862173+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics elects three Class II directors, ratifies PwC

## Summary
- Class II directors elected: Behbahani (14.5M for, 20.0M withheld), Menzel (33.5M for, 0.96M withheld), Kulkarni (14.2M for, 20.3M withheld); 8.5M broker non-votes each.
- Ratification of PwC as auditor for FY2025 passed: 42.48M for, 0.45M against, 59k abstain.
- Annual meeting held June 12, 2025 with 42.99M shares present out of 56.68M outstanding, establishing quorum.

## SEC filing metadata
- accession: 0001104659-25-058893
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465925058893/0001104659-25-058893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465925058893/tm2517877d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-058893
- JSON: https://secwatch.observer/filing/0001104659-25-058893.json
- Plain text: https://secwatch.observer/filing/0001104659-25-058893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.